Woody and Jean Durham were honored on October 13 in Chapel Hill for their volunteer service to UNC Lineberger Comprehensive Cancer Center at a dinner called “A Toast to Woody.”
Kimryn Rathmell, MD, PhD, thrives on discovery, whether in her lab developing a new experiment for kidney cancer or in her kitchen trying out a new food or cuisine.
Terry Magnuson, PhD, Sarah Graham Kenan Professor, Chair of the Department of Genetics, and Vice Dean for Research at the School of Medicine, is featured in a spotlight story on UNC-Chapel Hill's website.
UNC-Chapel Hill Chancellor Emeritus James Moeser talks with Shelley Earp, MD, director of the UNC Lineberger Comprehensive Cancer Center, about the creation and development of the cancer center. This discussion is the third in a series based on the book "Good to Great" by Jim Collins.
Grant from the Centers for Disease Control focuses on younger breast cancer patients
UNC scientists report that in early stage, asymptomatic non-small cell lung cancer, early brain recurrences are potentially detectable prior to surgery and recommend that physicians consider including a routine pre-operative staging brain MRI. In addition, patients whose tumors are determined to be higher risk based on the findings at surgery, should consider post-operative MRI to offer early treatment of unrecognized metastasis.
Dr. Nicholas Shaheen, professor in the UNC School of Medicine, adjunct professor in the UNC Gillings School of Global Public Health and director of the UNC Center for Esophageal Diseases and Swallowing, will co-direct Barrett’s Esophagus Translational Research Network (BETRNet) projects.
Jian Jin, PhD, an associate professor and director of medicinal chemistry in the Center for Integrative Chemical Biology and Drug Discovery at UNC-Chapel Hill, is featured in endeavors magazine.
Carol Shores, MD, PhD, FACS, has been interested in the link between viruses and cancer for over 20 years, after working on virus- associated cancers as a pre-doctoral fellow in the UNC Department of Biochemistry and Biophysics. Oropharyngeal cancers, like cervical cancer, are associated with human papilloma viruses and endemic Burkitt lymphoma, a childhood cancer in sub-Saharan Africa, is associated with Epstein-Barr virus.
CHAPEL HILL, N.C. - Patients who have high-risk non-melanoma skin carcinomas of the head and neck may benefit from concomitant radiotherapy and chemotherapy, according to a UNC-led study. Their study is the first to report on multiple patients with these skin carcinomas treated simultaneously with radio-and chemotherapy.
Noel Brewer, a professor of public health at UNC who has also studied HPV vaccine use, said the public controversy has been less harmful than the fact that many doctors simply don’t know or choose not to recommend it, or that many parents have insurance plans that don’t cover the vaccine or charge large co-pays for it.
Keith Amos, MD, quoted in The Huffington Post
Chapel Hill, NC – G-Zero Therapeutics, an RTP company started in 2008 based on technologies from the University of North Carolina at Chapel Hill, has been awarded a $3 million Phase II Small Business Innovation Research Grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Channing Der and his wife, Kathy, had already planned a 30th wedding anniversary trip to Kenya. After hearing Carolina alumnus and author Rye Barcott talk about his book, It Happened on the Way to War: A Marine’s Path to Peace, and describe the Carolina for Kibera program in Nairobi, Kenya, they knew they had to see the program in action.
Toolkit moves best practices to the community
Chapel Hill - A team of UNC scientists report that in laboratory studies, overexpression of a specific protein could be used as a prognostic marker and as a guide for therapeutic choices for patients with head and neck cancer. Their findings appear in the September 9, 2011 online issue of the journal Clinical Cancer Research.
CHAPEL HILL – When sperm meets egg, the chemical instructions that tag sperm cells must be erased so that human life can start anew. One way these instructions are erased is through demethylation, the removal of specific chemical tags or methyl groups that dot the underlying DNA of cells. Though scientists have known about this phenomenon for a decade, exactly how such “reprogramming” occurs has proved elusive.
Chapel Hill - A new type of nanoparticle developed in the laboratories at the University of North Carolina has shown potential for more effective delivery of chemotherapy to treat cancer. Wenbin Lin, PhD, Kenan Distinguished Professor of Chemistry and Pharmacy, and colleagues report their finding online in advance of print on September 14, 2011 in Angewandte Chemie, the German-based flagship chemistry journal.
CHAPEL HILL, N.C. – Weili Lin, PhD, professor of radiology, neurology and biomedical engineering and director of the UNC Biomedical Research Imaging Center, has been appointed The Dixie Lee Boney Soo Distinguished Professor in Neurological Medicine.
CHAPEL HILL – A team of over 250 researchers from more than 20 countries have discovered that common genetic variations contribute to a person’s risk of schizophrenia and bipolar disorder.
CHAPEL HILL – Within the immune system, a subtle balance exists between the cells that destroy alien pathogens and those that preserve the body’s own tissues. When the balance gets out of whack, the cells that normally target viruses or bacteria can go astray, attacking innocent cells and causing autoimmune and inflammatory disease.
Seventh annual event benefits cancer research and treatment in our community
Two recent grants from the National Science Foundation will support soft matter research at the University of North Carolina at Chapel Hill.
Kevin Weeks, a chemist at the University of North Carolina at Chapel Hill, has received an award from the National Institutes of Health to support innovative research on creating new drugs that work by binding to RNA.
UNC Lineberger patient Morgan Throckmorton was diagnosed with colon cancer in 2009 when she was 24 years old. She is now part of a UNC-led trial to test a new drug, Regorafinib.